To reach more patients across Europe, we're now a part of
emovis is honored and motivated to be considered one of the preferred partners by recognized CROs and sponsors. The CROs include IQVIA and PAREXEL, as well as the sponsor Pfizer in these partnerships. emovis is always interested in being the first choice for other sponsors of important sites.
PAREXEL: Site Alliance Programs
emovis has been a part of PAREXEL’s "Site Alliance Networks" since 2015. The "Site Alliance Network" of PAREXEL consists of 300 members and additional SMOs. Collaboratively, this network grants access to approximately 6,000 investigators worldwide. The SMOs alone have access to a total of approximately 7.5 million patients in more than 20 countries. This partnership is also a constant motivating factor for emovis to improve on an even greater level.
emovis has been admitted to the INSPIRE Program by Pfizer in 2013. INSPIRE stands for Investigator Networks, Site Partnerships and Infrastructure for Research Excellence. Participating in INSPIRE enables emovis to gain early insight in the PFIZER portfolio and access extensive information on clinical trials sponsored by Pfizer.
IQVIA: Partner Sites
Our special relationship with IQVIA has existed for over 10 years. During that time, emovis was included in the "Partner Sites" program and the partnership continues unchanged to this day.
Foundation member 2021
The BVMA (Bundesverband medizinischer Auftragsforschungsinstitute) is a federal association of clinical contract research organizations in Germany.
The DGPharMed (Deutsche Gesellschaft für pharmazeutische Medizin) is a german corporation for pharmaceutical medicine.
The BuVeBa (Bundesverband für Studienassistenten) is a federal association for research assistants.